Eisai hit with Cancer Drugs Fund 'double Whammy'
This article was originally published in Scrip
Executive Summary
Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.
You may also be interested in...
Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.